uniQure N.V. (0EE0.L)
USD 16.7
(1.06%)
USD 16.7
(1.06%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -282.87 Million USD | -97.59% |
| 2022 | -143.15 Million USD | -146.09% |
| 2021 | 310.61 Million USD | 347.65% |
| 2020 | -125.42 Million USD | -3.54% |
| 2019 | -121.14 Million USD | -37.3% |
| 2018 | -88.23 Million USD | -22.62% |
| 2017 | -71.95 Million USD | -0.02% |
| 2016 | -71.94 Million USD | 3.84% |
| 2015 | -74.82 Million USD | -81.86% |
| 2014 | -41.14 Million USD | -32.21% |
| 2013 | -31.11 Million USD | -65.81% |
| 2012 | -18.76 Million USD | 15.52% |
| 2011 | -22.21 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -40.22 Million USD | 15.12% |
| 2024 Q1 | -55.36 Million USD | 10.34% |
| 2024 Q2 | -47.39 Million USD | 14.39% |
| 2023 Q3 | -81.87 Million USD | -25.82% |
| 2023 Q4 | -61.74 Million USD | 24.58% |
| 2023 FY | -282.87 Million USD | -97.59% |
| 2023 Q1 | -74.17 Million USD | -379.88% |
| 2023 Q2 | -65.07 Million USD | 12.27% |
| 2022 FY | -143.15 Million USD | -146.09% |
| 2022 Q2 | -56.06 Million USD | -3.66% |
| 2022 Q1 | -54.08 Million USD | -2715.09% |
| 2022 Q4 | 26.5 Million USD | 144.53% |
| 2022 Q3 | -59.51 Million USD | -6.17% |
| 2021 Q2 | 398 Million USD | 995.24% |
| 2021 Q4 | 2.06 Million USD | 104.6% |
| 2021 Q3 | -45 Million USD | -111.31% |
| 2021 Q1 | -44.45 Million USD | -437.91% |
| 2021 FY | 310.61 Million USD | 347.65% |
| 2020 Q1 | -34.46 Million USD | -4.5% |
| 2020 Q3 | -44.49 Million USD | -16.44% |
| 2020 Q4 | -8.26 Million USD | 81.42% |
| 2020 FY | -125.42 Million USD | -3.54% |
| 2020 Q2 | -38.2 Million USD | -10.87% |
| 2019 Q3 | -31.32 Million USD | -6.8% |
| 2019 Q2 | -29.33 Million USD | -6.64% |
| 2019 Q1 | -27.5 Million USD | -13.62% |
| 2019 FY | -121.14 Million USD | -37.3% |
| 2019 Q4 | -32.97 Million USD | -5.28% |
| 2018 Q3 | -23.22 Million USD | -9.53% |
| 2018 Q1 | -19.59 Million USD | 13.45% |
| 2018 Q4 | -24.2 Million USD | -4.23% |
| 2018 FY | -88.23 Million USD | -22.62% |
| 2018 Q2 | -21.2 Million USD | -8.18% |
| 2017 Q4 | -22.64 Million USD | -144.15% |
| 2017 Q3 | -9.27 Million USD | 52.94% |
| 2017 Q2 | -19.7 Million USD | 0.04% |
| 2017 FY | -71.95 Million USD | -0.02% |
| 2017 Q1 | -19.71 Million USD | -69.89% |
| 2016 Q1 | -24.43 Million USD | -79.05% |
| 2016 FY | -71.94 Million USD | 3.84% |
| 2016 Q3 | -14.97 Million USD | 28.65% |
| 2016 Q2 | -20.99 Million USD | 14.1% |
| 2016 Q4 | -11.6 Million USD | 22.52% |
| 2015 FY | -74.82 Million USD | -81.86% |
| 2015 Q4 | -13.64 Million USD | 55.16% |
| 2015 Q1 | -9.42 Million USD | 8.87% |
| 2015 Q3 | -30.43 Million USD | -45.84% |
| 2015 Q2 | -20.87 Million USD | -121.35% |
| 2014 Q2 | -11.97 Million USD | -14.63% |
| 2014 Q3 | -10.01 Million USD | 16.38% |
| 2014 Q4 | -10.34 Million USD | -3.3% |
| 2014 FY | -41.14 Million USD | -32.21% |
| 2014 Q1 | -10.44 Million USD | -6.64% |
| 2013 Q1 | -6.51 Million USD | -7.54% |
| 2013 Q2 | -6.63 Million USD | -1.81% |
| 2013 Q3 | -7.26 Million USD | -9.49% |
| 2013 Q4 | -9.79 Million USD | -34.8% |
| 2013 FY | -31.11 Million USD | -65.81% |
| 2012 Q3 | -4.6 Million USD | 0.0% |
| 2012 FY | -18.76 Million USD | 15.52% |
| 2012 Q4 | -6.06 Million USD | -31.64% |
| 2011 FY | -22.21 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -169.18 Million USD | -67.2% |
| Dynavax Technologies Corporation | -37.02 Million USD | -663.938% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -5268.59% |
| Perrigo Company plc | 151.9 Million USD | 286.222% |
| Illumina, Inc. | -1.06 Billion USD | 73.539% |
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 104.124% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 38.581% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 97.99% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 114.308% |
| Heron Therapeutics, Inc. | -110.61 Million USD | -155.726% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 106.989% |
| Unity Biotechnology, Inc. | -44.66 Million USD | -533.289% |
| Waters Corporation | 817.67 Million USD | 134.595% |
| Biogen Inc. | 1.29 Billion USD | 121.813% |
| Sangamo Therapeutics, Inc. | -274 Million USD | -3.236% |
| Evolus, Inc. | -49.23 Million USD | -474.556% |
| Adicet Bio, Inc. | -152.03 Million USD | -86.053% |
| Cara Therapeutics, Inc. | -121.49 Million USD | -132.825% |
| bluebird bio, Inc. | -244.26 Million USD | -15.806% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | -81.837% |
| FibroGen, Inc. | -281.81 Million USD | -0.375% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 120.953% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | -527.524% |
| Homology Medicines, Inc. | -48.25 Million USD | -486.2% |
| Geron Corporation | -193.94 Million USD | -45.852% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | -0.247% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | -284.89% |
| Myriad Genetics, Inc. | -123.7 Million USD | -128.675% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -180.551% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 45.105% |
| Zoetis Inc. | 3.06 Billion USD | 109.217% |
| Abeona Therapeutics Inc. | -48.2 Million USD | -486.869% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 126.016% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 245.479% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 106.567% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | -622.476% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 20.032% |
| Atara Biotherapeutics, Inc. | -276 Million USD | -2.487% |
| Verastem, Inc. | -92.08 Million USD | -207.188% |
| Nektar Therapeutics | -137.42 Million USD | -105.837% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | -22.019% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | -190.55% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | -5.618% |
| OPKO Health, Inc. | -157.02 Million USD | -80.149% |
| Exelixis, Inc. | 170.88 Million USD | 265.533% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 212.743% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 363.671% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -407.337% |
| Imunon, Inc. | -21.03 Million USD | -1245.056% |
| Blueprint Medicines Corporation | -486.27 Million USD | 41.829% |
| Insmed Incorporated | -709.62 Million USD | 60.138% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 183.795% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 27.744% |
| TG Therapeutics, Inc. | 20.63 Million USD | 1470.964% |
| Incyte Corporation | 620.52 Million USD | 145.586% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 61.059% |